Serum thyroglobulin is associated with orbitopathy in Graves’ disease

por Khamisi, S., Lundqvist, M., Emadi, P., Almby, K., Ljunggren, Ö., Karlsson, F. A.
Publicado 2021

Vitamin D and bone metabolism in Graves’ disease: a prospective study

por Khamisi, S., Lundqvist, M., Rasmusson, A. J., Engström, B. E., Karlsson, F. A., Ljunggren, Ö.
Publicado 2022

Real-world effectiveness of osteoporosis treatment in the oldest old

por Ström, O., Lauppe, R., Ljunggren, Ö., Spångéus, A., Ortsäter, G., O’Kelly, J., Åkesson, K.
Publicado 2020

Risk of imminent fracture following a previous fracture in a Swedish database study

por Banefelt, J., Åkesson, K.E., Spångéus, A., Ljunggren, O., Karlsson, L., Ström, O., Ortsäter, G., Libanati, C., Toth, E.
Publicado 2019

Fracture rate and back pain during and after discontinuation of teriparatide: 36-month data from the European Forsteo Observational Study (EFOS)

por Fahrleitner-Pammer, A., Langdahl, B. L., Marin, F., Jakob, F., Karras, D., Barrett, A., Ljunggren, Ö., Walsh, J. B., Rajzbaum, G., Barker, C., Lems, W. F.
Publicado 2010

Effects of teriparatide in postmenopausal women with osteoporosis pre-treated with bisphosphonates: 36-month results from the European Forsteo Observational Study

por Jakob, F, Oertel, H, Langdahl, B, Ljunggren, O, Barrett, A, Karras, D, Walsh, J B, Fahrleitner-Pammer, A, Rajzbaum, G, Barker, C, Lems, W F, Marin, F
Publicado 2012

Effects of teriparatide in postmenopausal women with osteoporosis pre-treated with bisphosphonates: 36-month results from the European Forsteo Observational Study

por Jakob, F, Oertel, H, Langdahl, B, Ljunggren, O, Barrett, A, Karras, D, Walsh, J B, Fahrleitner-Pammer, A, Rajzbaum, G, Barker, C, Lems, W F, Marin, F
Publicado 2012